Although our first generation N,N-dialkyl/aryl CHC compounds are highly potent inhibitors, but in vivo efficacy studies required high doses (~50 mg/kg) for significant tumor growth inhibition in MCT1 expressing WiDr and MCT4 expressing MDA-MB-231 tumor models. Here, SLC16A1 is linked to neoplasm.